Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma
| Autor: | Victoria M L Cohen, Maria Tsimpida, Amit K. Arora, John L. Hungerford |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty genetic structures medicine.medical_treatment Brachytherapy Glaucoma Lesion medicine Humans Iris Neoplasms Melanoma Intraocular Pressure Aged Retrospective Studies Aged 80 and over Plaque radiotherapy business.industry Outcome measures Iris melanoma Retrospective cohort study Middle Aged medicine.disease eye diseases Surgery Ophthalmology Iris Malignant Melanoma Clinical Study Female Ruthenium Radioisotopes medicine.symptom business Follow-Up Studies |
| Zdroj: | Eye. 25:1607-1611 |
| ISSN: | 1476-5454 0950-222X |
| Popis: | Purpose To report the results of ruthenium-106 plaque radiotherapy for iris malignant melanoma. Methods A retrospective study of 15 patients with pure iris melanoma treated with ruthenium-106 plaque radiotherapy from June 1998 to June 2006. The main outcome measures were tumour control and ocular complications. Results Of the 15 patients, 8 had biopsy-proven melanoma (6 incisional and 2 excisional biopsies). In the remaining seven patients enlargement of the lesion was documented. The median follow-up was 96 months (ranging from 14 months to 12 years). Common radiation-related complications included cataract in 9 (60%) patients, dry eyes in 3 (20%) patients and elevated intraocular pressure in 4 (27%) patients. Vision was preserved in 80% of patients. Local tumour control was obtained in all patients. Conclusions Ruthenium-106 plaque radiotherapy is an effective treatment for primary malignant iris melanoma, resulting in excellent local control with preservation of vision. Main complications included cataract, dry eyes, and glaucoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|